Aim: This study was performed to determine the effects of glutamine enriched total parenteral nutrition (TPN) on the patients with acute pancreatitis (AP). Method: Forty patients with AP, who had Ranson's score between 2 and 4 received either standard TPN (control group) or TPN with glutamine (treatment group). The patients in the treatment group received TPN containing 0.3 g/kg/days glutamine. At the end of the study, patients were evaluated for nutritional and inflammatory parameters, length of TPN and length of hospital stay.
Introduction
Glutamine, which is synthesized in various cells such as skeletal, muscle, lungs and brain, is the most abundant amino acid in the plasma and intracellular amino-acid pool. Although glutamine is a nonessential amino acid, it is recognized as 'conditionally essential amino acid' because of the increased body's demand in catabolic state (Hall et al., 1996; Fürst et al., 1997; Oguz, 1998) .
It has been suggested that the support of the patients with acute pancreatitis (AP) with total parenteral nutrition (TPN) provides relaxation for gastrointestinal system and pancreas. Furthermore, the long-term ileus, respiratory and renal failure as well as severe metabolic disorders and surgical operations preclude the oral and enteral nutrition (EN) of patients with severe AP. TPN has been suggested in the management of the patients with AP for preventing the exocrine secretions so that autodigestion of pancreas. It has also been used as a support for optimal recovery as well as a life support (Havala et al., 1989; Latifi et al., 1991; Scolapio et al., 1999) .
In recent years, EN has been considered as a method, which has the priority in the nutrition of the patients with mild AP. However, TPN is still a choice for the patients suffering from the mild AP with nausea and vomit (Meier et al., 2002 (Meier et al., , 2006 .
Although TPN contribute to optimal recovery and proper function of the pancreas, longer period of TPN (over 10 days) administration increases the risk factors for acute inflammatory response and septicemia (McClave and Ritchie, 2000; Maroulis and Kalfarentzos, 2000) . To prevent these adverse effects, TPN is supplemented with glutamine in the form of dipeptide (alanyl-glutamine, glycyl-L glutamine) as a fuel for rapidly growing cells such as intestinal enterocytes, lymphocytes, macrophages and neutrophils (Hardy et al., 1993; Ziegler et al., 1996; Meier et al., 2002) . The results of previous studies have shown that glutamine-enriched TPN formulas improve the prognosis of the disease (Karner et al., 1989; O'Riordain et al., 1996; Griffiths et al., 1997; Ziegler et al., 1997; Morlion et al., 1998; Ockenga et al., 2002) .
This study was performed to determine the effects of early administration (at the first 48 h) of glutamine dipeptidesupplemented TPN on the nutritional status, occurrence of the complications and length of hospital stay of the patients with AP.
Materials and methods
This study was approved by a local ethical committee (Ethical Committee of Faculty of Medicine, University of Erciyes) and the procedures followed were in accordance with Helsinki Declaration. All patients were informed about the content of the study. This is a cross-sectional study that was conducted on patients with AP. The study was conducted at the Clinics of General Surgery, on 40 patients consisting of 17 male (42.5%) and 23 female (57.5%), aged between 20 and 81 years (mean age 58.9714 years) whose Ranson's score was lower than 4.
The patients who had been unable to eat for a week or longer period, and expected to require parenteral nutrition (PN) support and had not have any chronic diseases except pancreatitis were selected for the study.
AP was diagnosed by clinical examination, Ranson's diagnostic criteria and the radiologic criteria of pancreatitis (ultrasonography and Balthazar classification was based on computerized tomography). Serum amylase concentration was used to support the diagnosis of AP (the presence of threefold increase in serum concentrations).
Patients were randomly assigned to two groups as control and treatment group. The patients, who had nasogastric intolerance and were suffering from the mild AP with nausea and vomiting, were parenteral fed. The patients in control group received standard TPN, whereas the patients in treatment group received TPN supplemented with 0.3 g/kg/ days glutamine (Dipeptiven, Fresenius, Germany). There was no difference between the TPN solutions except glutamine supplementation. The basal energy requirements of patients were calculated by the equation of Schofield and Scrimshaw stress factors. Nonprotein energy/nitrogen rate was used for the determination of protein requirements (NPE/N ¼ 125/ 1 Â 6 ¼ 25). About 60 and 40% of the nonamino acid energy were provided with glucose (Dextrose 50%, Eczacıbas¸ı-Baxter, Turkey) and lipid (Intralipid 20%, Fresenius Kabi, Germany) solutions, respectively. The patients in treatment and control groups received standard amino-acid solution (FreAmine 10%, Eczacıbas¸ı-Baxter, Turkey) at a level of 1.170.3 and 1.470.3 g/kg/days, respectively ( Table 1 ). The TPN formula given to the patients in both group supplemented with the same levels of calcium (Calcium-Picken% 10, Adeka, Turkey), vitamin C (Redoxon, Roche, Switzerland), B group vitamins (Bepanthene, Roche, Switzerland) and trace elements (Tracutil-Braun, Germany). The TPN solution was prepared by the nutrition team of the hospital.
At the beginning and at the end of the study, height and weight of the patients were measured, and body mass index (BMI) was calculated. Blood samples were collected and sera were analyzed for glucose, blood urea nitrogen (BUN), creatinine, bilirubin, total protein, albumin, total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C) concentrations and aspartate aminotransferase (AST), alanine aminotransferase activities by commercial kits using an auto analyzer (MEGA, Merck). Electrolytes were determined by AVL 988-3 and hematological measurements were performed by Cell-Dyn 1700.
Low-density lipoprotein cholesterol (LDL-C) levels and very low-density lipoprotein (VLDL) levels were calculated by the Friedewald's formula (Friedewald et al., 1972) 
Serum zinc (Zn) and copper (Cu) concentrations were determined by flame atomic absorption spectrophotometer (Hitachi Z-8000, Tokyo, Japan). C-reactive protein (CRP) (Dade Behring 2) and transferrin were measured by nephelometric method (IMAGE), CD 4 and CD 8 measurements were carried out by commercial kit (Immunotech PN IM 0448-FITC) using flow cytometry.
Urine urea nitrogen was measured by photometric method from 24-h urine samples. Four points were added to obtained values to compensate the losses via different routes such as feces, hair, menstruation, skin and nail. Nitrogen balance 
Results
Ranson's scores were found as 2.770.9 in the group receiving TPN with glutamine and 2.870.8 in the group receiving TPN without glutamine (NS). It was accepted that there was no necrosis in mild AP according to the Balthazar's radiological classification. Thus, no sign of necrosis was found in both groups.
The patients in both groups lost weight, but the weight loss of the patients in the treatment group was less than control group (2.5 vs 2.7%). Serum total protein levels of the patients in treatment group unchanged whereas total protein concentrations of the patients in control group decreased by 3.2% (NS). Albumin levels decreased by 3.0 and 8.8% in treatment and control groups (NS), respectively. Serum transferrin levels of the patients increased by 11.7% in the treatment group (Po0.05) and decreased by 12.1% in the control group (NS).
The nitrogen balance of the patients in both groups was improved at the end of the study compare with the values obtained at the beginning of the study (Po0.05) ( Table 2) .
Complication was observed in eight of the patients (40%) in control group and in two of the patients (10%) in treatment group. The most common complication seen in both group was respiratory failure (53.4%). Any cardiac failure, sepsis due to catheter and resistant sepsis were not observed in the patient in treatment group but in control group, 23.0% of the patients showed cardiac failure and sepsis due to catheter and resistant sepsis were present in 15.4% of the patients. During the study, two (10%) patients in the treatment group and six (30%) patients in the control group died (Table 3) .
The mean length of the TPN administration was 10.573.6 (7-15) days for the patients in treatment group; this period was 11.672.5 (7-21) days for the patients in control group. Oral feeding was started at similar times in both groups (8.473.1 days for the treatment group and 8.572.7 days for the control group). The length of the hospital stay of the patients in the treatment group was shorter than the control Effects of glutamine-enriched TPN on AP H S¸ahin et al group (14.274.4 days vs 16.473.9 days). However, the differences between the groups were not statistically significant with regard to length of TPN, start of oral feeding and length of hospital stay (Table 4) . At the end of the study, slight but not significant changes were determined in both groups in fasting blood sugar, BUN, creatinine, serum Na, K, Cl, triglycerides, total cholesterol concentrations, AST, ALT and LDH activities, leukocytes, CD 4 , CD 8 , serum Zn, Ca and P levels compare to the values obtained at the beginning of the study. Significant decreases were determined in serum lipase, amylase activities and CRP levels in both groups (Po 0.05) ( Table 2) .
Discussion
If the patients with mild AP (Ranson's score o3) can begin oral feeding after 5-7 days, EN/PN is considered unnecessary. However, in several studies and guidelines, the superiority of EN/PN has been emphasized (McClave et al., 1997; Marik and Zaloga, 2004; Meier et al., 2006) . PN is still a choice in patient who could not be fed orally or intolerant. In patients included in this study, retching, nausea and vomiting was accompanying to abdominal pain therefore TPN was applied.
In this study, patients in the treatment groups and control groups were lost weight. Malnutrition owing to abdominal pain and malabsorption has been seen in about 30% of the patients with AP. In addition, these patients resemble to septic patients with regard to metabolic status. The increase in metabolic rate occurs owing to energy expenditure, proteolysis, and gluconeogenesis and insulin resistance. Delay in the starting of oral feeding (over 10 days) results in the increases in the risk of malnutrition of the patients. The patients with AP lose weight, and body functions decrease depending on the severity and length of the disease (Scolapio et al., 1999; Maroulis and Kalfarentzos, 2000; McClave and Ritchie, 2000; Meier et al., 2002) .
In this study, there was no change in total protein level of the patients who received glutamine-enriched TPN. Transferrin levels of these patients increased in contrast to the decreases in control group consistent with the results of the previous studies (Yoshida et al., 2001; Ockenga et al., 2002) .
In this study, urea nitrogen excretion with urine decreased in both groups thus nitrogen balance could be established. Nutritional support provides a rapid improvement in nitrogen balance of the patients with AP. In the body, glutamine is used for the nitrogen requirements of immune system cells, enterocytes, and also for nitrogen resources of metabolic activities, and for filling the glutamine pool (Ziegler et al., 1996; Fürst et al., 1997) . In some studies, it has been shown that TPN without glutamine had beneficial effects on the nitrogen balance like the glutamine-enriched TPN (Sitzman et al., 1989; Scolapio et al., 1999) .
The level of CRP, that is the most important biological function in the body is to recognize and to stimulate the clearance of the cell remnants, was decreased in both groups. The decrease in the treatment group was pronounced, but the values were still higher than the normal. The high CRP levels may be due to the presence of the factors that affecting the CRP levels such as fever, leukocytosis and surgical operation as well as the presence of the inflammation. In a previous study investigating the effects of standard and glutamine-enriched PN on AP, CRP levels were determined for the evaluation of systemic inflammatory response, and CRP concentrations of the patients had decreased in the treatment group, whereas CRP level in the control group had decreased at the first week and increased thereafter. Similarly a total leukocyte count was determined in both groups (Ockenga et al., 2002) .
Glutamine is, generally, accepted as an immunomodulatory agent. In many studies performed on human and animals, glutamine has been beneficial effects on the immune system cells and their functions, thus reduction in infection rates was observed (O'Riordain et al., 1996; Ziegler et al., 1998; Karwowska et al., 2001; Ockenga et al., 2002) . However, in some other studies, these effects have not been observed ( Van der Hulst et al., 1993 . Similarly, in this study, CD 4 and CD 8 counts were increased, but the increases did not reach statistical significance. The mean leukocyte counts of the patients in the treatment group reduced by 27.9% almost returning the normal levels, in contrast, leukocyte counts increased by 29.3% in the control group. The relationship between the increased peripheral blood leukocyte count and infections, trauma and acute response to inflammation is well known, and this increase is considered as a part of acute phase response. It was considered that the leucocytosis that was observed in this study might be related to the inflammation due to infection.
Several previous studies reported that glutamine supplementation to TPN shortens the length of hospital stay, reduces infection depended-complications, increases the survival rate and finally reduces overall treatment cost per patient (McBurney et al., 1994; Griffiths et al., 1997; Morlion et al., 1998; Ziegler et al., 1998; Neri et al., 2001; Ockenga et al., 2002) . In this study, although the difference between the groups was not statistically significant, the duration of the PN of the patients who received glutamine-enriched TPN was shorter than controls (10.573.6 days vs 11.672.5 days) Local and systemic complications occur frequently in AP patients. The systemic inflammatory response syndrome (SIRS) or insufficient functions of multiple organs, thus the development of necrosis in pancreas is considered to be responsible for the complications and deaths at the early stage. Pancreatic inflammation, which makes the treatment difficult, is the primary reason for the development of complications at the late stage of the infection. Pancreatic infections occur at the first 4 weeks of the disease and reach to peak levels at 2 or 3 weeks. It has been reported that pancreatic infections are responsible for 80% of the deaths in AP (Neoptolemos et al., 1998; Quamruddin and Chadwick, 2000) .
The nutritional support is considered to be effective in the prevention of the inflammation in AP (McClave et al., 1997; Guillou 1999; McClave and Ritchie, 2000) . Recent studies have shown that early enteral nutrition (EEN) provides better clinical course than TPN. Furthermore, some special nutritional substance like glutamine has potential benefits (Fish et al., 1997; Abou-Assi and O'Keefe, 2002) In many studies investigating the effects of glutamine, it was reported that complications were reduced by nutritional support (Ziegler et al., 1996 (Ziegler et al., , 1997 Morlion et al., 1998; Ockenga et al., 2002) . In this study, complications developed in 10% of the patients in treatment group, whereas in 40% of the patients in control group. Of 86.7% of the complications were seen in control group, whereas 13.3% of the complications were seen in treatment group. The most frequently seen complication was respiratory insufficiency (53.4%). A study was conducted by Kalfarentzos et al. (1991) that included on 67 patients with severe AP whose Ranson's score was 3.870.2. The authors applied the TPN at early stage (first 72 h) and found the complication and mortality rates as 23.6 and 13%, respectively in the patients who received TPN at early stage, and they found the complication rate as 9.5% and mortality rate as 38% in the patients who received TPN at the late stage of the disease.
In conclusion, the results of this study has shown that a beneficial effect of glutamine supplementation in patients with AP.
